Teva gains US FDA's blessing for Synribo in CML
This article was originally published in Scrip
Executive Summary
With the US FDA's 26 October accelerated approval of Teva's Synribo (omacetaxine mepesuccinate), a first-in-class cetaxine, patients with chronic myeloid leukemia (CML) in the chronic or accelerated phases and resistant or intolerant to two or more tyrosine kinase inhibitors (TKIs) have another treatment option for a disease in which there are few alternatives.